NASDAQ: ONTX was downgraded by Zacks.com from a “get” rating to a “hold” ranking in a research note released to financiers on Thursday, Zacks.com reports.
According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on discovering as well as developing little molecule medicine prospects to deal with cancer. The Firm‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Several various other equities research analysts additionally recently talked about the firm. Noble Financial editioned a “buy” ranking and released a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and set a “get” rating on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day moving average rate of $2.90 and a two-hundred day moving average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and an adverse web margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, compared to the consensus price quote of $0.06 million. Throughout the same quarter in the previous year, the firm published ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will upload -1.18 EPS for the current year.
A variety of hedge funds have recently dealt shares of ONTX. GSA Funding Partners LLP purchased a new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and various other institutional financiers own 13.36% of the business’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition and also development of oncology therapeutics. It focuses on uncovering and creating tiny particle drug candidates to deal with cancer cells. The firm was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA
. Obtain a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).
To learn more concerning research offerings from Zacks Investment Research, check out Zacks.com.
This instant information alert was produced by narrative science technology and also economic data from Market in order to provide viewers with the fastest as well as most precise coverage. This story was reviewed by Market’s editorial team prior to publication.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?
Prior to you think about Onconova Therapeutics, you’ll want to hear this.
Market monitors Wall Street’s top-rated and finest executing research experts and also the stocks they recommend to their customers on a daily basis. Market has determined the 5 stocks that cover analysts are silently whispering to their customers to purchase now prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the listing.
While Onconova Therapeutics currently has a “Buy” rating among analysts, premier experts think these 5 stocks are much better gets.